Until recently, the heart has been viewed as a terminally differentiated organ with no capacity for new cardiac myocyte (CM) formation. This view appears to be incorrect, in that we and others have been able to isolate cardiac-derived progenitor cells (CDPCs) from human myocardium. Extending these results, our recent studies indicate that cells expressing the stem cell surface marker c-kit can be isolated from human hearts immediately after explantation and subsequently induced to differentiate into CM via short-term co-culture with neonatal rat ventricular myocytes (RVMs). Though we typically find more c-kit+ cells usually in failing vs. nonfailing hearts, the need to replace these failing hearts via transplantation highlights the inadequacy of native cardiac repair mechanisms. Based on these findings, our broad working hypothesis is that increased c-kit+ CDPCs in failing human hearts include both lineage-negative c-kit+ and c-kit+/CD45(dim-moderate) cells that are each capable of new myocyte formation in vitro. In this context, the objective of this proposal is to quantify and characterize these distinct subpopulations of stem/progenitor cells within human hearts with an emphasis on elucidating their functional capacity for replication and CM differentiation.
Our first aim i s to identify what types of stem/progenitor cells are present in normal and failing human hearts. We will define distinct stem/progenitor subpopulations based on immunotyping of disaggregated myocardial cells with fluorescence microscopy and flow cytometry and perform complementary studies in tissue sections from the same hearts to define their distribution.
Our second aim i s to characterize replicative capacity of the selected CDPC subpopulations based on a combination of static assays (telomere length, telomerase activity and and p16INK4a expression) and functional assessment of proliferation rates.
Our third aim i s to characterize the cardiac myogenic potential of selected CDPC subpopulations derived from human hearts. These studies will define the rates and frequency of CM differentiation for sorted subpopulations under stardardized co-culture conditions, define whether cell contact is required for induction of CM differentiation by neonatal rat myocytes and identify secreted factors (chemokines or growth factors) that promote or augment rates of in vitro CM diffentiation in selected CDPC subpopulations. The clinical/therapeutic significance of this proposal is based on the premise that insights into the proliferative and cardiomyogenic potential of endogenous cardiac stem/progenitor cell subpopulations will promote progress towards therapeutic cardiac regeneration with or without cell therapy per se.
In recent successful experiments, we have isolated resident stem/progenitor cells from human hearts and induced their in vitro differentiation into contracting cardiac myocytes. Building on these findings, this research is focused on characterizing selected subpopulations of these stem/progenitor cells with an emphasis on elucidating their capacity for replication and differentiation into functioning cardiac myocytes. We contend that insights into the cardiomyogenic potential of endogenous cardiac stem/progenitor cells will promote progress towards therapeutic cardiac regeneration with or without cell therapy per se.
|Chen, Christina Yingxian; Caporizzo, Matthew A; Bedi, Kenneth et al. (2018) Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure. Nat Med 24:1225-1233|
|Peyster, Eliot G; Madabhushi, Anant; Margulies, Kenneth B (2018) Advanced Morphologic Analysis for Diagnosing Allograft Rejection: The Case of Cardiac Transplant Rejection. Transplantation 102:1230-1239|
|Robison, Patrick; Caporizzo, Matthew A; Ahmadzadeh, Hossein et al. (2016) Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes. Science 352:aaf0659|
|Bedi Jr, Kenneth C; Snyder, Nathaniel W; Brandimarto, Jeffrey et al. (2016) Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation 133:706-16|
|Lee, Dong I; Zhu, Guangshuo; Sasaki, Takashi et al. (2015) Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 519:472-6|
|Lambert, Rebekah; Srodulski, Sarah; Peng, Xiaoli et al. (2015) Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport. J Am Heart Assoc 4:e002183|
|Liu, Yichuan; Morley, Michael; Brandimarto, Jeffrey et al. (2015) RNA-Seq identifies novel myocardial gene expression signatures of heart failure. Genomics 105:83-9|
|Despa, Sanda; Sharma, Savita; Harris, Todd R et al. (2014) Cardioprotection by controlling hyperamylinemia in a ""humanized"" diabetic rat model. J Am Heart Assoc 3:|
|Despa, Sanda; Margulies, Kenneth B; Chen, Le et al. (2012) Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes: a study in humans and rats. Circ Res 110:598-608|
|Elser, Jeremy Alan; Purcell, Brendan P; Allana, Irshad A et al. (2012) Ischemia induces P-selectin-mediated selective progenitor cell engraftment in the isolated-perfused heart. J Mol Cell Cardiol 52:105-12|
Showing the most recent 10 out of 18 publications